Federated Hermes, Inc. Savara Inc Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Savara Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 3 shares of SVRA stock, worth $10. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$10

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.96 - $5.07 $11 - $15	3 New	3 $0
Q1 2024 May 14, 2024	BUY	$4.19 - $5.59 $4 - $5	1 New	1 $0
Q2 2021 Aug 16, 2021	SELL	$1.51 - $2.29 $529,126 - $802,450	-350,415 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$1.17 - $2.33 $1,104 - $2,199	-944 Reduced 0.27%	350,415 $729,000
Q4 2020 Feb 12, 2021	SELL	$1.0 - $1.47 $602 - $884	-602 Reduced 0.17%	351,359 $404,000
Q3 2020 Nov 12, 2020	BUY	$1.09 - $2.21 $1,685 - $3,416	1,546 Added 0.44%	351,961 $384,000
Q2 2020 Aug 13, 2020	BUY	$1.8 - $3.05 $630,277 - $1.07 Million	350,154 Added 134158.62%	350,415 $873,000
Q1 2020 May 13, 2020	BUY	$1.91 - $4.08 $204 - $436	107 Added 69.48%	261 $1,000
Q4 2019 Feb 14, 2020	BUY	$0.71 - $4.91 $109 - $756	154 New	154 $1,000

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

Nea Management Company, LLC Timonium, MD

24.5M
Shares

$82.2 Million
7.93% of portfolio
Bain Capital Life Sciences Investors, LLC Boston, MA

14.6M
Shares

$48.9 Million
11.08% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

12.4M
Shares

$41.5 Million
6.8% of portfolio
Wellington Management Group LLP Boston, MA

8.62M
Shares

$29 Million
0.01% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.16M
Shares

$27.4 Million
1.86% of portfolio

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account